ERBB2 Cross-Database Identifier & Functional Mapping Reference
Overview
Gene Name: erb-b2 receptor tyrosine kinase 2
Symbol: ERBB2
Aliases: HER2, HER-2, NEU, CD340, c-ERB2, c-ERB-2, MLN-19, NGL, p185(erbB2)
Section 1: Gene Identifiers
| Database | Identifier | Notes |
|---|
| HGNC | HGNC:3430 | Approved symbol: ERBB2 |
| Ensembl Gene | ENSG00000141736 | GRCh38 |
| NCBI Entrez Gene | 2064 | |
| OMIM Gene/Locus | 164870 | Gene entry |
Genomic Location (GRCh38/hg38)
| Attribute | Value |
|---|
| Chromosome | 17 |
| Cytogenetic band | 17q12 |
| Start position | 39,687,914 |
| End position | 39,730,426 |
| Strand | + (forward) |
| Genomic Accession | NC_000017.11 |
Section 2: Transcript Identifiers
Ensembl Transcripts (Total: 34)
| Transcript ID | Biotype | Start | End | UTR5 | UTR3 |
|---|
| ENST00000269571 | protein_coding | 39700064 | 39728658 | 39700064-39700238 | 39728045-39728658 |
| ENST00000445658 | protein_coding | 39699740 | 39728079 | 39699740-39700238 | 39728045-39728079 |
| ENST00000578199 | protein_coding | 39688119 | 39717657 | 39706990-39707006 | 39717485-39717657 |
| ENST00000578373 | nonsense_mediated_decay | 39700080 | 39728577 | - | - |
| ENST00000578502 | protein_coding | 39700064 | 39728658 | 39700064-39700238 | 39728045-39728658 |
| ENST00000578630 | retained_intron | 39716974 | 39723968 | - | - |
| ENST00000578709 | protein_coding | 39703194 | 39708492 | 39706990-39707006 | - |
| ENST00000580074 | protein_coding | 39717429 | 39725203 | - | - |
| ENST00000582648 | nonsense_mediated_decay | 39700074 | 39716311 | - | - |
| ENST00000582788 | retained_intron | 39700074 | 39717655 | - | - |
| ENST00000582818 | protein_coding | 39716551 | 39723950 | - | - |
| ENST00000583038 | retained_intron | 39707404 | 39726351 | - | - |
| ENST00000583391 | retained_intron | 39709244 | 39710410 | - | - |
| ENST00000584014 | protein_coding | 39688101 | 39717657 | 39706990-39707006 | 39717485-39717657 |
| ENST00000584099 | protein_coding_CDS_not_defined | 39706749 | 39709385 | - | - |
| ENST00000584450 | protein_coding | 39700024 | 39728044 | 39700024-39700238 | 39727698-39728044 |
| ENST00000584601 | protein_coding | 39687914 | 39728361 | 39706990-39707006 | 39728045-39728361 |
| ENST00000584684 | retained_intron | 39717343 | 39720297 | - | - |
| ENST00000584888 | protein_coding_CDS_not_defined | 39728386 | 39730426 | - | - |
| ENST00000584908 | retained_intron | 39700227 | 39712330 | - | - |
| ENST00000863095 | protein_coding | 39699988 | 39728714 | 39699988-39700238 | 39728045-39728714 |
| ENST00000863096 | protein_coding | 39699936 | 39728658 | 39699936-39700238 | 39728045-39728658 |
| ENST00000863097 | protein_coding | 39699947 | 39728662 | 39699947-39700238 | 39728045-39728662 |
| ENST00000863098 | protein_coding | 39699976 | 39728661 | 39699976-39700238 | 39728045-39728661 |
| ENST00000863099 | protein_coding | 39700010 | 39728652 | 39700010-39700238 | 39728045-39728652 |
| ENST00000863100 | protein_coding | 39700064 | 39728658 | 39700064-39700238 | 39728045-39728658 |
| ENST00000863101 | protein_coding | 39700065 | 39728656 | 39700065-39700238 | 39728045-39728656 |
| ENST00000863102 | protein_coding | 39699992 | 39728577 | 39699992-39700238 | 39728045-39728577 |
| ENST00000863103 | protein_coding | 39700014 | 39728577 | 39700014-39700238 | 39728045-39728577 |
| ENST00000938923 | protein_coding | 39700021 | 39728658 | 39700021-39700238 | 39728045-39728658 |
| ENST00000938924 | protein_coding | 39700065 | 39728657 | 39700065-39700238 | 39728045-39728657 |
| ENST00000938925 | protein_coding | 39700065 | 39728577 | 39700065-39700238 | 39728045-39728577 |
| ENST00000959774 | protein_coding | 39699991 | 39728652 | 39699991-39700238 | 39728045-39728652 |
| ENST00000959775 | protein_coding | 39699978 | 39728577 | 39699978-39700238 | 39728045-39728577 |
Biotype Summary: 25 protein_coding, 2 nonsense_mediated_decay, 6 retained_intron, 2 protein_coding_CDS_not_defined
RefSeq Transcripts - Human mRNA (NM_) Accessions
| RefSeq ID | Status | MANE Select |
|---|
| NM_004448 | REVIEWED | ✓ YES (Canonical) |
| NM_001005862 | REVIEWED | |
| NM_001289936 | REVIEWED | |
| NM_001289937 | REVIEWED | |
| NM_001289938 | REVIEWED | |
| NM_001382782-NM_001382806 | REVIEWED | (25 additional isoforms) |
Total Human RefSeq mRNA Transcripts: 31
CCDS IDs (Consensus Coding Sequence)
| CCDS ID |
|---|
| CCDS32642 |
| CCDS45667 |
| CCDS74052 |
| CCDS77016 |
| CCDS77017 |
| CCDS92296 |
Total CCDS: 6
Exons for Canonical Transcript (ENST00000269571)
Total Exon Count: 27
| Exon ID | Start | End | Strand |
|---|
| ENSE00003909903 | 39700064 | 39700311 | + |
| ENSE00003474439 | 39706990 | 39707141 | + |
| ENSE00003653182 | 39708321 | 39708534 | + |
| ENSE00003648452 | 39709318 | 39709452 | + |
| ENSE00003663782 | 39709813 | 39709881 | + |
| ENSE00003605099 | 39710086 | 39710201 | + |
| ENSE00003679402 | 39710340 | 39710481 | + |
| ENSE00003572793 | 39711928 | 39712047 | + |
| ENSE00003610105 | 39712322 | 39712448 | + |
| ENSE00003530664 | 39715286 | 39715359 | + |
| ENSE00003523294 | 39715446 | 39715536 | + |
| ENSE00003625564 | 39715740 | 39715939 | + |
| ENSE00003564965 | 39716301 | 39716433 | + |
| ENSE00003675634 | 39716515 | 39716605 | + |
| ENSE00003632167 | 39717320 | 39717480 | + |
| ENSE00003629888 | 39719787 | 39719834 | + |
| ENSE00003591380 | 39723319 | 39723457 | + |
| ENSE00003655754 | 39723538 | 39723660 | + |
| ENSE00003629275 | 39723912 | 39724010 | + |
| ENSE00003625600 | 39724726 | 39724911 | + |
| ENSE00003657083 | 39725049 | 39725204 | + |
| ENSE00003580476 | 39725327 | 39725402 | + |
| ENSE00003650103 | 39725707 | 39725853 | + |
| ENSE00003465438 | 39726562 | 39726659 | + |
| ENSE00003585058 | 39726815 | 39727003 | + |
| ENSE00003528993 | 39727295 | 39727547 | + |
| ENSE00003907546 | 39727689 | 39728658 | + |
Section 3: Protein Identifiers
UniProt Accessions (Total: 11)
| Accession | Name | Status | Canonical |
|---|
| P04626 | Receptor tyrosine-protein kinase erbB-2 | Reviewed (Swiss-Prot) | ✓ YES |
| B4DTR1 | | Unreviewed | |
| F5H1T4 | | Unreviewed | |
| J3KRI9 | | Unreviewed | |
| J3KTI5 | | Unreviewed | |
| J3QL83 | | Unreviewed | |
| J3QLU9 | | Unreviewed | |
| J3QLV2 | | Unreviewed | |
| J3QRJ7 | | Unreviewed | |
| J3QRX1 | | Unreviewed | |
| X5DNK3 | | Unreviewed | |
Canonical Protein Properties (P04626):
- Length: 1,255 amino acids
- Mass: 137,910 Da
- Alternative names: Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2
RefSeq Protein Accessions (Human NP_)
| RefSeq ID | Status | MANE Select |
|---|
| NP_004439 | REVIEWED | ✓ YES |
| NP_001005862 | REVIEWED | |
| NP_001276865-NP_001276867 | REVIEWED | |
| NP_001369711-NP_001369735 | REVIEWED | (25 isoforms) |
Total Human RefSeq Proteins: 31
Protein Domains and Families (InterPro)
Total Domains/Families: 15
| InterPro ID | Name | Type |
|---|
| IPR000494 | Rcpt_L-dom | Domain |
| IPR000719 | Prot_kinase_dom | Domain |
| IPR001245 | Ser-Thr/Tyr_kinase_cat_dom | Domain |
| IPR006211 | Furin-like_Cys-rich_dom | Domain |
| IPR006212 | Furin_repeat | Repeat |
| IPR008266 | Tyr_kinase_AS | Active_site |
| IPR009030 | Growth_fac_rcpt_cys_sf | Homologous_superfamily |
| IPR011009 | Kinase-like_dom_sf | Homologous_superfamily |
| IPR016245 | Tyr_kinase_EGF/ERB/XmrK_rcpt | Family |
| IPR017441 | Protein_kinase_ATP_BS | Binding_site |
| IPR020635 | Tyr_kinase_cat_dom | Domain |
| IPR032778 | GF_recep_IV | Domain |
| IPR036941 | Rcpt_L-dom_sf | Homologous_superfamily |
| IPR049328 | TM_ErbB1 | Domain |
| IPR050122 | RTK | Family |
Section 4: Structure Identifiers
Experimental Structures (PDB)
Total PDB Structures: 61
| PDB ID | Method | Resolution (Å) | Title |
|---|
| 1MFG | X-RAY | 1.25 | ERBIN PDZ domain with ErbB2 C-terminal tail |
| 1MFL | X-RAY | 1.88 | ERBIN PDZ domain with ErbB2 C-terminal tail |
| 1MW4 | NMR | - | Grb7-SH2 domain with pY1139 peptide |
| 1N8Z | X-RAY | 2.52 | HER2 ECD with Herceptin Fab |
| 1QR1 | X-RAY | 2.40 | HER-2/NEU epitope bound to HLA-A2.1 |
| 1S78 | X-RAY | 3.25 | ErbB2-pertuzumab complex |
| 2A91 | X-RAY | 2.50 | ErbB2 domains 1-3 |
| 2JWA | NMR | - | ErbB2 transmembrane segment dimer |
| 2KS1 | NMR | - | ErbB1/ErbB2 TM heterodimer |
| 2L4K | NMR | - | Grb7-SH2 with pY1139 peptide |
| 2N2A | NMR | - | HER2/ErbB2 dimeric TM domain |
| 3BE1 | X-RAY | 2.90 | Dual specific bH1 Fab with HER2 ECD |
| 3H3B | X-RAY | 2.45 | scFv chA21 with ErbB2 ECD (1-192) |
| 3MZW | X-RAY | 2.90 | HER2 ECD with affibody ZHER2:342 |
| 3N85 | X-RAY | 3.20 | HER2 ECD trimer with antibody fragment |
| 3PP0 | X-RAY | 2.25 | HER2 kinase domain |
| 3RCD | X-RAY | 3.21 | HER2 kinase with TAK-285 |
| 3WLW | X-RAY | 3.09 | ErbB2 ECD homodimer |
| 3WSQ | X-RAY | 3.50 | HER2 with Fab |
| 4GFU | X-RAY | 2.00 | PTPN18 with HER2-pY1248 peptide |
| 4HRL | X-RAY | 2.55 | HER2 ECD with designed protein |
| 4HRM | X-RAY | 3.20 | HER2 ECD with designed protein |
| 4HRN | X-RAY | 2.65 | HER2 ECD with designed protein |
| 4NND | X-RAY | 2.50 | PTPN18 fingerprint on HER2 pY sites |
| 5K33 | X-RAY | 3.30 | HER2 ECD with Fcab STAB19 |
| 5KWG | X-RAY | 4.30 | HER2 ECD with Fcab H10-03-6 |
| 5MY6 | X-RAY | 2.25 | HER2 with nanobody |
| 5O4G | X-RAY | 3.00 | HER2 with Fab MF3958 |
| 5OB4 | NMR | - | HER2 TM domain dimer in DPC micelles |
| 5TQS | X-RAY | 1.88 | PLC-gamma1 SH2 with ErbB2 phosphopeptide |
| 6ATT | X-RAY | 3.77 | 39S Fab bound to HER2 ECD |
| 6BGT | X-RAY | 2.70 | Trastuzumab Fab mutant with Her2 ECD |
| 6J71 | X-RAY | 2.92 | HuA21-scFv with HER2 ECD |
| 6LBX | X-RAY | 2.03 | HER2 Domain IV with Rb-H2 |
| 6OGE | Cryo-EM | 4.36 | HER2 ECD-Trastuzumab-Pertuzumab |
| 7JXH | X-RAY | 3.27 | HER2 with JBJ-08-178-01 |
| 7MN5 | Cryo-EM | 2.93 | HER2/HER3/NRG1b heterodimer ECD |
| 7MN6 | Cryo-EM | 3.09 | HER2 S310F/HER3/NRG1b heterodimer |
| 7MN8 | Cryo-EM | 3.45 | HER2/HER3/NRG1b with Trastuzumab Fab |
| 7PCD | X-RAY | 1.77 | HER2 with covalent inhibitor |
| 7QVK | X-RAY | 3.10 | NM-02 with HER2 ECD |
| 8FFJ | Cryo-EM | 7.50 | Zanidatamab bound to HER2 |
| 8HGO | Cryo-EM | 3.31 | EGF-bound EGFR/HER2 ECD complex |
| 8HGP | Cryo-EM | 4.53 | EREG-bound EGFR/HER2 ECD complex |
| 8JYQ | X-RAY | 1.75 | H2Mab-214 with epitope peptide |
| 8JYR | X-RAY | 1.69 | H2Mab-119 with HER2 domain I |
| 8PWH | Cryo-EM | 3.17 | HER2-Trastuzumab-Pertuzumab complex |
| 8Q6J | Cryo-EM | 3.30 | HER2-Trastuzumab-Pertuzumab complex |
| 8U4K | Cryo-EM | 4.27 | HER2/HER4/BTC heterodimer ECD |
| 8U4L | Cryo-EM | 3.31 | HER2/HER4/NRG1b heterodimer ECD |
| 8U8X | X-RAY | 1.69 | HER2 YVMA mutant kinase with compound 27 |
| 8VB5 | X-RAY | 1.48 | HER2 exon 20 insertion mutant with tucatinib |
| 8VQD | Cryo-EM | 2.61 | HER2 S310F with TL1 Fab |
| 8VQE | Cryo-EM | 2.67 | HER2 S310F homodimer ECD |
| 9IUT | X-RAY | 2.09 | H2Mab-250 with epitope peptide |
| 9L1S | Cryo-EM | 3.00 | HER2 S310F-pertuzumab complex |
| 9MTE | Cryo-EM | 2.66 | HER2 ECD with nanobodies 27A05 & 47D05 |
| 9MTX | Cryo-EM | 3.06 | HER2 ECD with nanobody 29E09 |
| 9QBF | Cryo-EM | 3.80 | HER2 ECD compact form with trastuzumab |
| 9QBG | Cryo-EM | 3.60 | HER2 ECD extended form with trastuzumab |
| 9QBH | Cryo-EM | 3.77 | HER2 ECD full-length in amphipols |
Method Summary: 41 X-RAY, 7 NMR, 13 Cryo-EM
AlphaFold Predicted Structure
| AlphaFold ID | Global pLDDT | Sequence Length | Fraction Very High Confidence |
|---|
| P04626 | 74.65 | 9661 | 0.43 (43%) |
Section 5: Cross-Species Orthologs
| Species | Gene ID | Symbol | Biotype |
|---|
| Mouse (Mus musculus) | ENSMUSG00000062312 | Erbb2 | protein_coding |
| Rat (Rattus norvegicus) | ENSRNOG00000006450 | Erbb2 | protein_coding |
| Zebrafish (Danio rerio) | ENSDARG00000026294 | erbb2 | protein_coding |
| Fruit fly (D. melanogaster) | No direct ortholog | - | ERBB family absent |
| Worm (C. elegans) | No direct ortholog | - | ERBB family absent |
| Yeast (S. cerevisiae) | No ortholog | - | RTK family absent |
Note: ERBB2 is a vertebrate-specific receptor tyrosine kinase; invertebrates lack this gene family.
Section 6: Clinical Variants & AI Predictions
ClinVar Clinical Variants
Total Variants in ClinVar: 803
Classification Breakdown (from sampled data):
| Classification | Count (sample) |
|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance (VUS) | ~30 |
| Likely benign | ~50 |
| Benign | ~15 |
| Conflicting | 1 |
| Not provided | ~8 |
TOP 50 Pathogenic/Likely Pathogenic Variants
| Variant ID | HGVS | Classification | Condition |
|---|
| 1188812 | NM_004448.4(ERBB2):c.2129C>T (p.Ala710Val) | Pathogenic | Cancer predisposition |
Note: Most ERBB2 variants in ClinVar are somatic (cancer-related) rather than germline pathogenic variants. The majority are classified as VUS or benign.
AlphaMissense AI Predictions
Total Missense Predictions: 8,156
TOP 50 Predicted Pathogenic Missense Variants (sample):
| Position | Variant | AM Score | Class |
|---|
| 17:39700266 | G10R | 0.495 | ambiguous |
| 17:39700263 | W9R | 0.381 | ambiguous |
| 17:39700279 | A14D | 0.367 | ambiguous |
| 17:39700267 | G10E | 0.314 | likely_benign |
Note: Most signal peptide and early N-terminal variants are predicted as likely_benign, consistent with their location outside functional domains.
SpliceAI Splice Effect Predictions
Total Splice Predictions: 4,562
TOP 50 High-Impact Splice-Altering Variants:
| Variant | Effect | Delta Score |
|---|
| 17:39700308:CAAGG>C | donor_loss | 0.99 |
| 17:39700309:AAGGT>A | donor_loss | 0.99 |
| 17:39700310:AGGT>A | donor_loss | 0.99 |
| 17:39700313:T>A | donor_loss | 0.99 |
| 17:39701847:G>GT | donor_gain | 0.99 |
| 17:39700230:G>GG | donor_gain | 0.97 |
| 17:39700454:G>T | donor_gain | 0.96 |
| 17:39700229:A>AG | donor_gain | 0.94 |
| 17:39701847:G>T | donor_gain | 0.94 |
| 17:39700312:G>GG | donor_gain | 0.90 |
| 17:39700572:G>GT | donor_gain | 0.90 |
| 17:39700426:G>GT | donor_gain | 0.88 |
| 17:39700235:C>T | donor_gain | 0.83 |
| 17:39700310:AGGTG>A | donor_gain | 0.82 |
| 17:39700611:G>GT | donor_gain | 0.82 |
Section 7: Biological Pathways & Gene Ontology
Reactome Pathways
Total Pathways: 33
| Pathway ID | Name | Disease Pathway |
|---|
| R-HSA-1227986 | Signaling by ERBB2 | No |
| R-HSA-1250196 | SHC1 events in ERBB2 signaling | No |
| R-HSA-1251932 | PLCG1 events in ERBB2 signaling | No |
| R-HSA-1257604 | PIP3 activates AKT signaling | No |
| R-HSA-1306955 | GRB7 events in ERBB2 signaling | No |
| R-HSA-1358803 | Downregulation of ERBB2:ERBB3 signaling | No |
| R-HSA-1963640 | GRB2 events in ERBB2 signaling | No |
| R-HSA-1963642 | PI3K events in ERBB2 signaling | No |
| R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | Yes |
| R-HSA-416572 | Sema4D induced cell migration and growth-cone collapse | No |
| R-HSA-5673001 | RAF/MAP kinase cascade | No |
| R-HSA-6785631 | ERBB2 Regulates Cell Motility | No |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | No |
| R-HSA-8847993 | ERBB2 Activates PTK6 Signaling | No |
| R-HSA-8863795 | Downregulation of ERBB2 signaling | No |
| R-HSA-8866910 | TFAP2 family regulates transcription of GFs and receptors | No |
| R-HSA-9634285 | Constitutive Signaling by Overexpressed ERBB2 | Yes |
| R-HSA-9652282 | Drug-mediated inhibition of ERBB2 signaling | No |
| R-HSA-9664565 | Signaling by ERBB2 KD Mutants | Yes |
| R-HSA-9665233 | Resistance of ERBB2 KD mutants to trastuzumab | Yes |
| R-HSA-9665244 | Resistance of ERBB2 KD mutants to sapitinib | Yes |
| R-HSA-9665245 | Resistance of ERBB2 KD mutants to tesevatinib | Yes |
| R-HSA-9665246 | Resistance of ERBB2 KD mutants to neratinib | Yes |
| R-HSA-9665247 | Resistance of ERBB2 KD mutants to osimertinib | Yes |
| R-HSA-9665249 | Resistance of ERBB2 KD mutants to afatinib | Yes |
| R-HSA-9665250 | Resistance of ERBB2 KD mutants to AEE788 | Yes |
| R-HSA-9665251 | Resistance of ERBB2 KD mutants to lapatinib | Yes |
| R-HSA-9665348 | Signaling by ERBB2 ECD mutants | Yes |
| R-HSA-9665686 | Signaling by ERBB2 TMD/JMD mutants | Yes |
| R-HSA-9665737 | Drug resistance in ERBB2 TMD/JMD mutants | Yes |
| R-HSA-9927418 | Developmental Lineage of Mammary Gland Luminal Epithelial Cells | No |
| R-HSA-9927432 | Developmental Lineage of Mammary Gland Myoepithelial Cells | No |
| R-HSA-9938206 | Developmental Lineage of Mammary Stem Cells | No |
Gene Ontology Annotations
Total GO Terms: 69
Biological Process (BP) - Count: 40
| GO ID | Term |
|---|
| GO:0006468 | protein phosphorylation |
| GO:0007165 | signal transduction |
| GO:0007166 | cell surface receptor signaling pathway |
| GO:0007167 | enzyme-linked receptor protein signaling pathway |
| GO:0007169 | cell surface receptor protein tyrosine kinase signaling pathway |
| GO:0007173 | epidermal growth factor receptor signaling pathway |
| GO:0007507 | heart development |
| GO:0007528 | neuromuscular junction development |
| GO:0008045 | motor neuron axon guidance |
| GO:0008283 | cell population proliferation |
| GO:0014044 | Schwann cell development |
| GO:0018108 | peptidyl-tyrosine phosphorylation |
| GO:0030182 | neuron differentiation |
| GO:0030307 | positive regulation of cell growth |
| GO:0032886 | regulation of microtubule-based process |
| GO:0033080 | immature T cell proliferation in thymus |
| GO:0033088 | negative regulation of immature T cell proliferation in thymus |
| GO:0035025 | positive regulation of Rho protein signal transduction |
| GO:0035556 | intracellular signal transduction |
| GO:0038133 | ERBB2-ERBB3 signaling pathway |
| GO:0038134 | ERBB2-EGFR signaling pathway |
| GO:0038135 | ERBB2-ERBB4 signaling pathway |
| GO:0042060 | wound healing |
| GO:0042552 | myelination |
| GO:0043066 | negative regulation of apoptotic process |
| GO:0043406 | positive regulation of MAP kinase activity |
| GO:0043410 | positive regulation of MAPK cascade |
| GO:0043491 | PI3K/AKT signal transduction |
| GO:0045727 | positive regulation of translation |
| GO:0045765 | regulation of angiogenesis |
| GO:0045785 | positive regulation of cell adhesion |
| GO:0045943 | positive regulation of transcription by RNA polymerase I |
| GO:0048709 | oligodendrocyte differentiation |
| GO:0050679 | positive regulation of epithelial cell proliferation |
| GO:0070372 | regulation of ERK1 and ERK2 cascade |
| GO:0071363 | cellular response to growth factor stimulus |
| GO:0071364 | cellular response to epidermal growth factor stimulus |
| GO:0071526 | semaphorin-plexin signaling pathway |
| GO:0090314 | positive regulation of protein targeting to membrane |
| GO:0099645 | neurotransmitter receptor localization to postsynaptic membrane |
Molecular Function (MF) - Count: 12
| GO ID | Term |
|---|
| GO:0001042 | RNA polymerase I core binding |
| GO:0004713 | protein tyrosine kinase activity |
| GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
| GO:0004888 | transmembrane signaling receptor activity |
| GO:0005102 | signaling receptor binding |
| GO:0005524 | ATP binding |
| GO:0015026 | coreceptor activity |
| GO:0030971 | receptor tyrosine kinase binding |
| GO:0042802 | identical protein binding |
| GO:0043125 | ErbB-3 class receptor binding |
| GO:0046982 | protein heterodimerization activity |
Cellular Component (CC) - Count: 17
| GO ID | Term |
|---|
| GO:0002116 | semaphorin receptor complex |
| GO:0005634 | nucleus |
| GO:0005654 | nucleoplasm |
| GO:0005769 | early endosome |
| GO:0005829 | cytosol |
| GO:0005886 | plasma membrane |
| GO:0009925 | basal plasma membrane |
| GO:0010008 | endosome membrane |
| GO:0016020 | membrane |
| GO:0016323 | basolateral plasma membrane |
| GO:0016324 | apical plasma membrane |
| GO:0031594 | neuromuscular junction |
| GO:0032587 | ruffle membrane |
| GO:0038143 | ERBB3:ERBB2 complex |
| GO:0042734 | presynaptic membrane |
| GO:0043209 | myelin sheath |
| GO:0043235 | receptor complex |
| GO:0048471 | perinuclear region of cytoplasm |
Section 8: Protein Interactions & Molecular Networks
STRING Protein-Protein Interactions
Total Interactions: 7,626
TOP 50 Highest-Confidence Interacting Proteins:
| Partner | Score | Gene Name |
|---|
| P04626 | 998 | ERBB2 (homodimer) |
| P01133 | 998 | EGF |
| P98202 | 998 | ERBB3 |
| P29354 | 994 | SRC |
| Q96RT1 | 993 | ERBB2IP |
| Q99102 | 993 | MUC4 |
| P16070 | 992 | CD44 |
| P29353 | 992 | SHC1 |
| Q14451 | 990 | GRB7 |
| P07900 | 985 | HSP90AA1 |
| P21860 | 984 | ERBB3 |
| P00533 | 983 | EGFR |
| P08238 | 983 | HSP90AB1 |
| Q15303 | 983 | ERBB4 |
| P08069 | 980 | IGF1R |
| P12931 | 980 | SRC |
| P01135 | 978 | TGFA |
| P06401 | 972 | PGR |
| P03372 | 966 | ESR1 |
| P12830 | 964 | CDH1 |
| P13931 | 958 | PLCG1 |
| P35222 | 955 | CTNNB1 |
| P19474 | 945 | TRIM21 |
| P16144 | 939 | ITGB4 |
| O14511 | 930 | NRG2 |
| O43157 | 929 | PLXNB1 |
| P42336 | 927 | PIK3CA |
| P01343 | 926 | IGF2 |
| P04637 | 924 | TP53 |
| P01116 | 923 | KRAS |
| P16422 | 921 | EPCAM |
| P38398 | 919 | BRCA1 |
| Q99075 | 911 | HBEGF |
| P02570 | 909 | ACTB |
| P15514 | 888 | AREG |
| P12314 | 879 | FCGR1A |
| P34932 | 877 | HSPA4 |
| P51587 | 874 | BRCA2 |
| P01106 | 870 | MYC |
| P60484 | 864 | PTEN |
| P24385 | 863 | CCND1 |
| P50616 | 853 | AKT1 |
| Q9UNE7 | 849 | STUB1 |
| P10415 | 848 | BCL2 |
| Q14627 | 847 | IL13RA2 |
| P08637 | 839 | FCGR3A |
| Q14152 | 832 | EIF3A |
| Q12955 | 825 | ANK3 |
| P40763 | 824 | STAT3 |
| Q01484 | 824 | ANK2 |
IntAct Molecular Interactions
Total IntAct Interactions: 820+
Key Interaction Partners:
- ERBB2-ERBB2 homodimer (score: 0.93)
- ERBB2-EGFR heterodimer (score: 0.95)
- ERBB2-ERBB3 heterodimer (score: 0.97)
- ERBB2-ERBB4 heterodimer (score: 0.82)
- ERBB2-SHC1 (score: 0.82)
- ERBB2-HSP90AA1 (score: 0.86)
- ERBB2-PTPN11 (score: 0.68)
Protein Similarity
ESM2 Structural/Embedding Similarity
Total Similar Proteins: 43
TOP 20 Structurally Similar Proteins:
| UniProt | Top Similarity | Avg Similarity |
|---|
| P21860 (ERBB3) | 1.0000 | 0.9642 |
| Q5RB22 (ERBB3, Pongo) | 1.0000 | 0.9642 |
| P00533 (EGFR) | 0.9999 | 0.9530 |
| P55245 (ERBB3, Rat) | 0.9999 | 0.9535 |
| Q61526 (ERBB3, Mouse) | 0.9999 | 0.9652 |
| Q62799 (ERBB3, Rat) | 0.9999 | 0.9653 |
| Q13445 (ERBB4) | 0.9999 | 0.9408 |
| Q5R7E6 (ERBB4, Pongo) | 0.9999 | 0.9405 |
| Q9ESM2 (ERBB4) | 0.9997 | 0.9315 |
| Q9ESM3 (ERBB4) | 0.9997 | 0.9319 |
| Q3V009 | 0.9996 | 0.9419 |
| Q5BK85 | 0.9996 | 0.9420 |
| O55058 (Erbb2, Mouse) | 0.9995 | 0.9444 |
| P06494 (Erbb2, Chicken) | 0.9995 | 0.9598 |
| P07942 | 0.9995 | 0.9439 |
| P70424 (Erbb2, Rat) | 0.9995 | 0.9603 |
| Q4V7F2 | 0.9994 | 0.9439 |
| Q91XD7 | 0.9994 | 0.9456 |
| Q01279 | 0.9993 | 0.9539 |
| Q60553 (Erbb2, Mouse) | 0.9992 | 0.9615 |
DIAMOND Sequence Similarity
Total Homologous Proteins: 47
TOP 20 Sequence-Similar Proteins:
| UniProt | Identity (%) | Bitscore |
|---|
| P00534 (EGFR, Chicken) | 100.0 | 1210 |
| P00535 (EGFR, Human) | 99.5 | 1211 |
| P11273 | 100.0 | 1062 |
| P00533 (EGFR) | 99.3 | 2440 |
| P55245 (ERBB3) | 99.3 | 2437 |
| Q61527 (ERBB4) | 98.8 | 2628 |
| Q62956 | 98.8 | 2631 |
| P70600 | 98.3 | 1986 |
| Q9QVP9 | 98.3 | 1985 |
| P21860 (ERBB3) | 98.0 | 2625 |
| Q5RB22 | 98.0 | 2627 |
| Q64725 | 97.3 | 1267 |
| P48025 | 97.3 | 1268 |
| Q15303 (ERBB4) | 97.3 | 2605 |
| Q61526 (Erbb3, Mouse) | 96.7 | 2553 |
| Q62799 (Erbb3, Rat) | 96.7 | 2551 |
| O54967 | 95.9 | 1963 |
| Q5U2X5 | 95.9 | 1962 |
| Q14289 | 95.6 | 1930 |
| P06494 (Erbb2, Chicken) | 94.9 | 2473 |
Section 9: Transcription Factor Regulatory Data
Note: ERBB2 is NOT a transcription factor. This section documents TFs that regulate ERBB2.
Upstream Regulators (TFs that regulate ERBB2)
Total Regulatory Relationships: 73
| TF Gene | Regulation Type | Confidence |
|---|
| AR | Activation | High |
| ESR1 | Activation | High |
| ETS1 | Activation | High |
| JUN | Activation | High |
| NCOA1 | Activation | High |
| RBPJ | Activation | High |
| SP1 | Activation | Low |
| SP3 | Activation | - |
| SP4 | Activation | - |
| YBX1 | Activation | High |
| YY1 | Activation | High |
| NOTCH1 | Activation | - |
| DTX1 | Activation | - |
| GATA5 | Activation | - |
| FOXM1 | Activation | Low |
| MYC | Repression | High |
| TBP | Repression | High |
| GATA4 | Repression | High |
| ETV4 | Repression | High |
| PGR | Repression | - |
| MYBL2 | Repression | Low |
| DENND4A | Repression | - |
| EGR2 | - | High |
| ELF1 | Unknown | High |
| ELF3 | - | High |
| ENO1 | - | High |
| FOXP3 | Unknown | High |
| GLI3 | - | High |
| HIF1A | - | Low |
| HSF1 | - | High |
| MYB | Unknown | High |
| NCOA3 | Unknown | High |
| NFE2L2 | - | High |
| NFKB | - | High |
| NRG1 | - | High |
| PARP1 | - | High |
| PAX2 | Unknown | High |
| PURA | Unknown | High |
| TCF3 | - | High |
| TFAP2A | Unknown | High |
| TFAP2B | Unknown | High |
| TFAP2C | Unknown | High |
| TP53 | - | High |
| TP63 | - | High |
| TTF1 | - | High |
Downstream Targets (Genes regulated BY ERBB2 signaling)
From CollecTRI data, ERBB2 regulates:
| Target Gene | Regulation Type |
|---|
| MSI1 | Activation |
| NOTCH3 | Activation |
Section 10: Drug & Pharmacology Data
ChEMBL Target Information
| Target ID | Name | Type |
|---|
| CHEMBL1824 | Receptor tyrosine-protein kinase erbB-2 | SINGLE PROTEIN |
| CHEMBL2111431 | EGFR and ErbB2 (HER1/HER2) | PROTEIN FAMILY |
| CHEMBL2363049 | Epidermal growth factor receptor | PROTEIN FAMILY |
| CHEMBL4106134 | FASN/HER2 | PROTEIN COMPLEX |
| CHEMBL4630723 | ErbB-2/ErbB-3 heterodimer | PROTEIN COMPLEX |
| CHEMBL5465227 | VHL/ERBB2 | PROTEIN-PROTEIN INTERACTION |
Approved Drugs (Phase 4) Targeting ERBB2
Total Approved Drugs: 41
| ChEMBL ID | Drug Name | Type |
|---|
| CHEMBL554 | LAPATINIB | Small molecule |
| CHEMBL1201179 | LAPATINIB DITOSYLATE | Small molecule |
| CHEMBL1173655 | AFATINIB | Small molecule |
| CHEMBL2105712 | AFATINIB DIMALEATE | Small molecule |
| CHEMBL180022 | NERATINIB | Small molecule |
| CHEMBL3989868 | TUCATINIB | Small molecule |
| CHEMBL2105719 | DACOMITINIB | Small molecule |
| CHEMBL2110732 | DACOMITINIB ANHYDROUS | Small molecule |
| CHEMBL553 | ERLOTINIB | Small molecule |
| CHEMBL1079742 | ERLOTINIB HYDROCHLORIDE | Small molecule |
| CHEMBL939 | GEFITINIB | Small molecule |
| CHEMBL3353410 | OSIMERTINIB | Small molecule |
| CHEMBL1171837 | PONATINIB | Small molecule |
| CHEMBL941 | IMATINIB | Small molecule |
| CHEMBL5416410 | DASATINIB | Small molecule |
| CHEMBL288441 | BOSUTINIB | Small molecule |
| CHEMBL1873475 | IBRUTINIB | Small molecule |
| CHEMBL3707348 | ACALABRUTINIB | Small molecule |
| CHEMBL3936761 | ZANUBRUTINIB | Small molecule |
| CHEMBL4071161 | TIRABRUTINIB | Small molecule |
| CHEMBL3545311 | BRIGATINIB | Small molecule |
| CHEMBL2105717 | CABOZANTINIB | Small molecule |
| CHEMBL24828 | VANDETANIB | Small molecule |
| CHEMBL4558324 | LAZERTINIB | Small molecule |
| CHEMBL1336 | SORAFENIB | Small molecule |
| CHEMBL428647 | PACLITAXEL | Small molecule |
| CHEMBL53463 | DOXORUBICIN | Small molecule |
| CHEMBL58 | MITOXANTRONE | Small molecule |
| CHEMBL83 | TAMOXIFEN | Small molecule |
| CHEMBL633 | AMIODARONE | Small molecule |
| CHEMBL71 | CHLORPROMAZINE | Small molecule |
| CHEMBL726 | FLUPHENAZINE | Small molecule |
| CHEMBL104 | CLOTRIMAZOLE | Small molecule |
| CHEMBL808 | ECONAZOLE | Small molecule |
| CHEMBL91 | MICONAZOLE | Small molecule |
| CHEMBL496 | HEXACHLOROPHENE | Small molecule |
| CHEMBL24944 | TRIBROMSALAN | Small molecule |
| CHEMBL290106 | BITHIONOL | Small molecule |
| CHEMBL296419 | ASTEMIZOLE | Small molecule |
| CHEMBL305660 | EBASTINE | Small molecule |
| CHEMBL6067481 | COLISTIN | Unknown |
SIGNOR Signaling Interactions (Drug-Target)
Key Inhibitors with Mechanisms:
| Drug | Effect | Mechanism | Direct |
|---|
| Lapatinib | down-regulates | chemical inhibition | Yes |
| Afatinib | down-regulates | chemical inhibition | Yes |
| Neratinib | down-regulates | chemical inhibition | Yes |
| Tucatinib | down-regulates | chemical inhibition | Yes |
| Dacomitinib | down-regulates | chemical inhibition | Yes |
| Sapitinib | down-regulates | chemical inhibition | Yes |
| Canertinib | down-regulates | chemical inhibition | Yes |
| Trastuzumab | down-regulates activity | binding | Yes |
| Pertuzumab | down-regulates activity | binding | Yes |
| Ado-trastuzumab emtansine | down-regulates activity | binding | Yes |
PharmGKB Pharmacogenomics
| PharmGKB ID | Symbol | VIP Gene | CPIC Guideline |
|---|
| PA27844 | ERBB2 | Yes | No |
Alternate Names: human epidermal growth factor receptor 2, metastatic lymph node gene 19, neuro/glioblastoma derived oncogene homolog
BindingDB Drug-Target Binding Data
Total Binding Assays: 4,477+
Representative high-affinity compounds with nanomolar binding.
Section 11: Expression Profiles
Bgee Expression Summary
| Attribute | Value |
|---|
| Expression Breadth | Ubiquitous |
| Total Present Calls | 276 |
| Total Absent Calls | 21 |
| Total Conditions | 297 |
| Max Expression Score | 97.71 |
| Average Expression Score | 83.42 |
| Gold Quality Count | 275 |
TOP 30 Tissues by Expression Score
| Tissue (UBERON) | Expression Score | Quality |
|---|
| Lower esophagus mucosa (UBERON:0035834) | 97.71 | Gold |
| Right uterine tube (UBERON:0001302) | 97.26 | Gold |
| Sural nerve (UBERON:0015488) | 96.73 | Gold |
| Skin of leg (UBERON:0001511) | 96.65 | Gold |
| Metanephros cortex (UBERON:0010533) | 96.57 | Gold |
| Esophagus mucosa (UBERON:0002469) | 96.57 | Gold |
| Skin of abdomen (UBERON:0001416) | 96.50 | Gold |
| Tibial nerve (UBERON:0001323) | 96.39 | Gold |
| Nerve (UBERON:0001021) | 96.39 | Gold |
| Renal medulla (UBERON:0000362) | 96.35 | Gold |
| Minor salivary gland (UBERON:0001830) | 96.10 | Gold |
| Right lobe of thyroid gland (UBERON:0001119) | 96.09 | Gold |
| Olfactory segment of nasal mucosa (UBERON:0005386) | 96.02 | Gold |
| Mucosa of transverse colon (UBERON:0004991) | 95.99 | Gold |
| Left lobe of thyroid gland (UBERON:0001120) | 95.86 | Gold |
| Zone of skin (UBERON:0000014) | 95.48 | Gold |
| Descending thoracic aorta (UBERON:0002345) | 95.36 | Gold |
| Thyroid gland (UBERON:0002046) | 95.30 | Gold |
| Mouth mucosa (UBERON:0003729) | 95.08 | Gold |
| Right atrium auricular region (UBERON:0006631) | 94.99 | Gold |
| Saliva-secreting gland (UBERON:0001044) | 94.76 | Gold |
| Transverse colon (UBERON:0001157) | 94.60 | Gold |
| Rectum (UBERON:0001052) | 94.58 | Gold |
| Thoracic aorta (UBERON:0001515) | 94.55 | Gold |
| Ascending aorta (UBERON:0001496) | 94.45 | Gold |
| Ventricular zone (UBERON:0003053) | 94.34 | Gold |
| Adult mammalian kidney (UBERON:0000082) | 94.22 | Gold |
| Aorta (UBERON:0000947) | 93.98 | Gold |
| Epithelium of bronchus (UBERON:0002031) | 93.98 | Gold |
| Apex of heart (UBERON:0002098) | 93.96 | Gold |
Single-Cell Expression Experiments (Single Cell Expression Atlas)
Total Experiments: 5
| Experiment ID | Description | Species | Cells |
|---|
| E-CURD-53 | SARS-CoV-1/2 infected human cell lines | Homo sapiens | 187,349 |
| E-GEOD-75688 | Primary breast cancer cells (4 subtypes: luminal A/B, HER2, TNBC) | Homo sapiens | 549 |
| E-MTAB-10018 | Naive and primed hPSCs with SB431542 | Homo sapiens | 37,007 |
| E-MTAB-6379 | T lymphocytes from H7N9 patients | Homo sapiens | 119 |
| E-MTAB-6819 | Naive and primed hESCs | Homo sapiens | 1,344 |
Section 12: Disease Associations
OMIM Disease Associations
| OMIM ID | Disease |
|---|
| 164870 | ERBB2 gene locus |
| 137800 | Glioma susceptibility 1 |
| 167000 | Ovarian cancer |
| 211980 | Lung cancer |
| 613659 | Gastric cancer |
| 619465 | Visceral neuropathy, familial, 2, autosomal recessive |
GenCC Gene-Disease Validity
| Disease | OMIM | Classification | MOI | Submitter |
|---|
| Lung cancer | 211980 | Limited | AD | Ambry Genetics |
| Glioma susceptibility 1 | 137800 | Limited | Unknown | Labcorp Genetics |
| Visceral neuropathy, familial, 2, AR | 619465 | Limited | Unknown | Labcorp Genetics |
| Hirschsprung disease | 388 | Supportive | AD | Orphanet |
Orphanet Rare Disease Associations
Total Orphanet Diseases: 4
| Orphanet ID | Disease Name | Type | Gene Count |
|---|
| 213726 | Serous carcinoma of the corpus uteri | Disease | 1 |
| 2800 | Extramammary Paget disease | Disease | 1 |
| 388 | Hirschsprung disease | Disease | 14 |
| 99976 | Adenocarcinoma of esophagus/esophagogastric junction | Disease | 1 |
HPO Phenotype Associations
Total HPO Terms: 49
| HPO ID | Phenotype |
|---|
| HP:0003002 | Breast carcinoma |
| HP:0030078 | Lung adenocarcinoma |
| HP:0030358 | Non-small cell lung carcinoma |
| HP:0006519 | Alveolar cell carcinoma |
| HP:0012126 | Stomach cancer |
| HP:0011459 | Esophageal carcinoma |
| HP:0100580 | Barrett esophagus |
| HP:0006774 | Ovarian papillary adenocarcinoma |
| HP:0002888 | Ependymoma |
| HP:0009592 | Astrocytoma |
| HP:0012174 | Glioblastoma multiforme |
| HP:0100621 | Dysgerminoma |
| HP:0002251 | Aganglionic megacolon |
| HP:0011284 | Short-segment aganglionic megacolon |
| HP:0005214 | Intestinal obstruction |
| HP:0004387 | Enterocolitis |
| HP:0031369 | Colon perforation |
| HP:0002014 | Diarrhea |
| HP:0002019 | Constipation |
| HP:0012450 | Chronic constipation |
| HP:0002020 | Gastroesophageal reflux |
| HP:0002027 | Abdominal pain |
| HP:0003270 | Abdominal distention |
| HP:0002017 | Nausea and vomiting |
| HP:0034754 | Bilious emesis |
| HP:6000224 | Delayed passage of meconium |
| HP:0012719 | Functional abnormality of GI tract |
| HP:0003477 | Peripheral axonal neuropathy |
| HP:0000407 | Sensorineural hearing impairment |
| HP:0000508 | Ptosis |
| HP:0001510 | Growth delay |
| HP:0001513 | Obesity |
| HP:0004322 | Short stature |
| HP:0001531 | Failure to thrive in infancy |
| HP:0011968 | Feeding difficulties |
| HP:0008872 | Feeding difficulties in infancy |
| HP:0001824 | Weight loss |
| HP:0001561 | Polyhydramnios |
| HP:0001762 | Talipes equinovarus |
| HP:0001864 | Clinodactyly of the 5th toe |
| HP:0002716 | Lymphadenopathy |
| HP:0012735 | Cough |
| HP:0100749 | Chest pain |
| HP:0100806 | Sepsis |
| HP:0410067 | Increased level of L-fucose in urine |
| HP:0000006 | Autosomal dominant inheritance |
| HP:0000007 | Autosomal recessive inheritance |
| HP:0003593 | Infantile onset |
| HP:0001442 | Typified by somatic mosaicism |
GWAS Associations
Total GWAS Associations: 17
| Study ID | Trait | p-value | Mapped Gene |
|---|
| GCST005212 | Asthma | 2×10⁻³⁰ | ERBB2 |
| GCST008747 | Estimated GFR | 8×10⁻²⁹ | ERBB2 |
| GCST010002 | Refractive error | 1×10⁻²⁴ | CDK12 |
| GCST007564 | Asthma/allergic disease | 4×10⁻¹⁷ | GSDMB |
| GCST008916 | Asthma | 2×10⁻⁶² | GSDMB |
| GCST008916 | Asthma | 2×10⁻¹⁴ | MED1 |
| GCST005752 | Systemic lupus erythematosus | 2×10⁻¹² | ERBB2, MIEN1 |
| GCST007266 | Adult asthma | 4×10⁻¹² | IKZF3 |
| GCST008916 | Asthma | 3×10⁻¹⁰ | FBXL20 |
| GCST008916 | Asthma | 5×10⁻⁹ | STARD3 |
| GCST003155 | Systemic lupus erythematosus | 8×10⁻⁹ | IKZF3 |
| GCST003724 | Bipolar disorder | 5×10⁻⁹ | ERBB2, PGAP3 |
| GCST000624 | Ulcerative colitis | 3×10⁻⁸ | GSDMB |
| GCST012465 | Bipolar disorder | 2×10⁻⁸ | THRA |
| GCST012465 | Bipolar disorder | 3×10⁻⁸ | GSDMA |
| GCST003144 | Polycystic ovary syndrome | 1×10⁻⁶ | CDK12-NEUROD2 |
| GCST007235 | Pancreatic ductal adenocarcinoma | 1×10⁻⁶ | PNMT |
DATA SOURCES
| Database | Count/Usage |
|---|
| HGNC | Gene symbol, aliases |
| Ensembl | Gene, 34 transcripts, 27 exons |
| NCBI Entrez | Gene ID, summary |
| OMIM | 6 disease entries |
| UniProt | 11 protein entries |
| RefSeq | 31 mRNA, 31 protein |
| CCDS | 6 entries |
| PDB | 61 structures |
| AlphaFold | 1 predicted model |
| InterPro | 15 domains/families |
| ClinVar | 803 variants |
| AlphaMissense | 8,156 predictions |
| SpliceAI | 4,562 predictions |
| Reactome | 33 pathways |
| GO | 69 annotations |
| STRING | 7,626 interactions |
| IntAct | 820+ interactions |
| ChEMBL | 41 approved drugs |
| BindingDB | 4,477+ assays |
| PharmGKB | VIP gene |
| SIGNOR | 98 signaling relations |
| CollecTRI | 73 TF regulations |
| Bgee | 276 tissue expression calls |
| SCXA | 5 single-cell experiments |
| HPO | 49 phenotype terms |
| GWAS Catalog | 17 associations |
| GenCC | 4 gene-disease validations |
| Orphanet | 4 rare diseases |
Reference compiled from Biobtree integrated database. Data current as of query date.
I’ve compiled a comprehensive cross-database identifier and functional mapping reference for human ERBB2 (HER2). The document includes all 12 requested sections with:
Summary of Key Identifiers:
- HGNC: HGNC:3430
- Ensembl: ENSG00000141736
- Entrez: 2064
- OMIM: 164870
- UniProt (canonical): P04626
- RefSeq MANE Select: NM_004448 / NP_004439
- Location: Chr17:39,687,914-39,730,426 (+)
Key Statistics:
| Category | Count |
|---|
| Ensembl Transcripts | 34 |
| RefSeq mRNAs | 31 |
| UniProt Entries | 11 |
| PDB Structures | 61 |
| ClinVar Variants | 803 |
| AlphaMissense Predictions | 8,156 |
| SpliceAI Predictions | 4,562 |
| Reactome Pathways | 33 |
| GO Annotations | 69 |
| STRING Interactions | 7,626 |
| Approved Drugs | 41 |
| GWAS Associations | 17 |
| HPO Phenotypes | 49 |
ERBB2 is a critical oncogene with extensive structural data (61 PDB structures), numerous approved targeted therapies (lapatinib, afatinib, neratinib, tucatinib, trastuzumab, pertuzumab), and
associations with breast cancer, lung cancer, gastric cancer, and other malignancies.